9-aminocamptothecin has been researched along with Agranulocytosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahut, W; Grem, JL; Ismail, AS; Leguizamo, J; Liang, MD; Pang, J; Quinn, M; Takimoto, CH | 1 |
| Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W | 1 |
2 trial(s) available for 9-aminocamptothecin and Agranulocytosis
| Article | Year |
|---|---|
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Topics: Acetamides; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Camptothecin; Colloids; Drug Resistance, Neoplasm; Excipients; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms | 2003 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome | 1997 |